|
BE787901A
(fr)
|
1971-09-11 |
1972-12-18 |
Freistaat Bayern Represente Pa |
Vaccin antivariolique
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
JPH0795954B2
(ja)
|
1982-11-30 |
1995-10-18 |
アメリカ合衆国 |
外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
|
|
GB8508845D0
(en)
|
1985-04-04 |
1985-05-09 |
Hoffmann La Roche |
Vaccinia dna
|
|
US5445953A
(en)
|
1991-08-26 |
1995-08-29 |
Immuno Aktiengesellschaft |
Direct molecular cloning of a modified poxvirus genome
|
|
EP1380651A2
(en)
|
1991-08-26 |
2004-01-14 |
Baxter Healthcare S.A. |
Recombinant fowlpox virus with intact FPV-tk-gene
|
|
DE69229390T2
(de)
|
1991-08-26 |
1999-11-11 |
Immuno Ag, Wien |
Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
|
|
AU5679394A
(en)
|
1992-11-25 |
1994-06-22 |
International Biotechnology Laboratories, Inc. |
Hepatitis b virus vaccines
|
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
EP0942747A1
(en)
|
1996-08-26 |
1999-09-22 |
Chiron Corporation |
Postinfection human immunodeficiency virus (hiv) vaccination therapy
|
|
US6962708B1
(en)
|
1997-02-28 |
2005-11-08 |
Acambis, Inc. |
Chimeric flavivirus vaccines
|
|
AUPP380598A0
(en)
|
1998-05-29 |
1998-06-25 |
Commonwealth Scientific And Industrial Research Organisation |
Genetically manipulated entomopoxvirus
|
|
US6294176B1
(en)
|
1998-07-10 |
2001-09-25 |
Schering-Plough Veterinary Corp. |
Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
|
|
WO2001092470A2
(en)
|
2000-03-02 |
2001-12-06 |
Emory University |
Dna expression vectors and methods of use
|
|
US8623379B2
(en)
|
2000-03-02 |
2014-01-07 |
Emory University |
Compositions and methods for generating an immune response
|
|
PT1372710E
(pt)
|
2001-03-08 |
2009-12-21 |
Us Gov Health & Human Serv |
Vam modificado que expressa os genes gag e pol do envelope de vih
|
|
EP1279404A1
(en)
|
2001-07-26 |
2003-01-29 |
Istituto Superiore di Sanità |
Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
|
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
|
US7211378B2
(en)
*
|
2002-01-31 |
2007-05-01 |
Wisconsin Alumni Research Foundation |
Filovirus vectors and noninfectious filovirus-based particles
|
|
US7025970B2
(en)
|
2002-03-15 |
2006-04-11 |
Baxter International Inc. |
Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
|
|
PL218318B1
(pl)
|
2002-05-16 |
2014-11-28 |
Bavarian Nordic As |
Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
|
|
US20060088909A1
(en)
|
2002-05-17 |
2006-04-27 |
Compans Richard W |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
US9045727B2
(en)
|
2002-05-17 |
2015-06-02 |
Emory University |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
WO2003106648A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Diadexus, Inc. |
Compositions and methods relating to breast specific genes and proteins
|
|
DE10249390A1
(de)
|
2002-10-23 |
2004-05-13 |
Ruprecht-Karls-Universität Heidelberg |
Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
|
|
US20040109876A1
(en)
|
2002-11-25 |
2004-06-10 |
Kureha Chemical Industry Co., Ltd. |
Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
|
|
AU2003293675B2
(en)
|
2002-11-25 |
2009-04-23 |
Bavarian Nordic A/S |
Recombinant poxvirus comprising at least two cowpox ATI promoters
|
|
EP1601333B1
(en)
|
2003-02-20 |
2013-01-23 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services |
Novel insertion sites in pox vectors
|
|
EP1518932A1
(en)
*
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
US20060099225A1
(en)
|
2004-04-13 |
2006-05-11 |
Sina Bavari |
Generation of virus-like particles and use as panfilovirus vaccine
|
|
EP2497831B1
(en)
|
2004-05-25 |
2014-07-16 |
Oregon Health and Science University |
TB vaccination using HCMV-based vaccine vectors
|
|
ES2539010T3
(es)
*
|
2004-08-27 |
2015-06-25 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C
|
|
EP1683870A1
(en)
*
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
JP2008543276A
(ja)
*
|
2005-03-30 |
2008-12-04 |
ミネルバ バイオテクノロジーズ コーポレーション |
Ｍｕｃ１発現細胞の増殖
|
|
WO2006130525A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
ES2611975T3
(es)
|
2006-06-20 |
2017-05-11 |
Transgene S.A. |
Procedimiento para producir poxvirus y composiciones de poxvirus
|
|
CA2657648A1
(en)
|
2006-07-13 |
2008-01-17 |
Emory University |
Virosomes, methods of preparation, and immunogenic compositions
|
|
WO2008142479A2
(en)
|
2006-08-25 |
2008-11-27 |
The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services |
Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
|
|
US20090092628A1
(en)
|
2007-03-02 |
2009-04-09 |
James Mullins |
Conserved-element vaccines and methods for designing conserved-element vaccines
|
|
CA2688548A1
(en)
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
JP6035503B2
(ja)
|
2007-05-31 |
2016-11-30 |
アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク |
ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
|
|
US11202775B2
(en)
|
2007-09-25 |
2021-12-21 |
Minerva Biotechnologies Corporation |
Methods for treatment of cancer
|
|
WO2009079564A2
(en)
|
2007-12-17 |
2009-06-25 |
Emory University |
Immunogenic compositions and methods of use thereof
|
|
AU2009319979B2
(en)
|
2008-11-03 |
2016-10-20 |
Takeda Vaccines, Inc. |
Improved methods for isolating enveloped virus-based VLPs free of infectious agents
|
|
CA2774475A1
(en)
|
2009-09-16 |
2011-03-24 |
The Administrators Of The Tulane Educational Fund |
Lassa virus-like particles and methods of production thereof
|
|
AP2012006258A0
(en)
|
2009-10-13 |
2012-06-30 |
Geovax Inc |
Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
|
|
AU2010306559B2
(en)
*
|
2009-10-16 |
2015-07-16 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . |
Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
|
|
CN102844663B
(zh)
*
|
2010-01-27 |
2016-01-06 |
俄勒冈健康科学大学 |
基于巨细胞病毒的免疫原性制剂
|
|
WO2011103417A2
(en)
|
2010-02-18 |
2011-08-25 |
Emory University Of Technology Transfer |
Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
|
|
US20120052082A1
(en)
|
2010-04-09 |
2012-03-01 |
Zetra Biologicals, LLC |
Cross-protective influenza vaccine
|
|
WO2011130627A2
(en)
|
2010-04-16 |
2011-10-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Chimpanzee adenoviral vector-based filovirus vaccines
|
|
CN103209701B
(zh)
|
2010-06-11 |
2016-08-03 |
乔治亚大学研究基金公司 |
免疫原性疫苗
|
|
AU2012212463B2
(en)
*
|
2011-01-31 |
2016-07-07 |
Nanotherapeutics, Inc. |
Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
|
|
US9683020B2
(en)
|
2011-08-01 |
2017-06-20 |
Emory University |
VLPS containing ligands and methods related thereto
|
|
WO2013059498A1
(en)
|
2011-10-18 |
2013-04-25 |
Geovax, Inc. |
Mva vectors expressing polypeptides and having high level production in certain cell lines
|
|
US9463238B2
(en)
|
2011-12-09 |
2016-10-11 |
Bavarian Nordic A/S |
Recombinant poxvirus vector comprising tetanus toxin fragment C
|
|
US20150140068A1
(en)
|
2012-07-06 |
2015-05-21 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
EP2945649B1
(en)
|
2013-01-22 |
2018-12-12 |
Oxford University Innovation Limited |
Composition and uses thereof
|
|
WO2015009946A1
(en)
|
2013-07-17 |
2015-01-22 |
Emory University |
Method of increasing immune response to hiv antigens
|
|
AU2014340201B2
(en)
|
2013-10-23 |
2019-02-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
|
|
WO2015066715A1
(en)
|
2013-11-04 |
2015-05-07 |
Viracell Advanced Products, Llc |
Virus-like particles and methods related thereto
|
|
CA2946606C
(en)
|
2014-05-13 |
2023-06-06 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3
|
|
CA2959105C
(en)
*
|
2014-09-03 |
2023-10-17 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
WO2016068919A1
(en)
|
2014-10-29 |
2016-05-06 |
Geovax, Inc. |
Combination therapy for treating viral reservoirs
|
|
US11701418B2
(en)
|
2015-01-12 |
2023-07-18 |
Geovax, Inc. |
Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
|
|
US10072058B2
(en)
|
2015-04-29 |
2018-09-11 |
Emory University |
Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
|
|
CA3011014A1
(en)
|
2016-01-08 |
2017-07-13 |
Geovax, Inc. |
Compositions and methods for generating an immune response to a tumor associated antigen
|
|
WO2017136419A1
(en)
|
2016-02-03 |
2017-08-10 |
Geovax Inc. |
Compositions and methods for generating an immune response to a flavivirus
|
|
CA3014419A1
(en)
|
2016-02-16 |
2017-08-24 |
Geovax Inc. |
Multivalent hiv vaccine boost compositions and methods of use
|
|
WO2017210181A1
(en)
|
2016-05-30 |
2017-12-07 |
Geovax Inc. |
Compositions and methods for generating an immune response to hepatitis b virus
|
|
WO2018195447A1
(en)
|
2017-04-20 |
2018-10-25 |
Geovax Labs, Inc. |
Recombinant mva-based hiv immunogens and uses thereof
|
|
WO2019018501A1
(en)
|
2017-07-18 |
2019-01-24 |
Geovax Inc. |
COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE
|
|
US20210220469A1
(en)
|
2017-08-25 |
2021-07-22 |
Geovax, Inc. |
Immuno-Oncology Compositions and Methods for Use Thereof
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
WO2020247547A1
(en)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Cancer vaccine compositions and methods for use thereof
|